Experienced in Intertrigo

Dr. Adnan Nasir

Dermatology
Wake Dermatology Associates PA
4414 Lake Boone Trl, Suite 408, 
Raleigh, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in Intertrigo
Wake Dermatology Associates PA
4414 Lake Boone Trl, Suite 408, 
Raleigh, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Adnan Nasir is a Dermatologist in Raleigh, North Carolina. Dr. Nasir is rated as an Experienced provider by MediFind in the treatment of Intertrigo. His top areas of expertise are Giant Congenital Melanocytic Nevus, Familial Atypical Multiple Mole Melanoma Syndrome, Giant Congenital Nevus, and Neurocutaneous Melanosis. Dr. Nasir is currently accepting new patients.

His clinical research consists of co-authoring 16 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Dermatology
Licenses
Dermatology in NC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

WAKE DERMATOLOGY ASSOCIATES PA
4414 Lake Boone Trl, Suite 408, Raleigh, NC 27607

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Evaluation of Depression and Anxiety in Chemotherapy Patients
Evaluation of Depression and Anxiety in Chemotherapy Patients
Enrollment Status: Recruiting
Publish Date: April 04, 2023
Intervention Type: Behavioral
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase 2, Open Label Study to Evaluate the Efficacy, Safety and Tolerability of VP-102 in Subjects With Common Warts (Verruca Vulgaris)
A Phase 2, Open Label Study to Evaluate the Efficacy, Safety and Tolerability of VP-102 in Subjects With Common Warts (Verruca Vulgaris)
Enrollment Status: Completed
Publish Date: November 27, 2024
Intervention Type: Combination product
Study Phase: Phase 2
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: September 18, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: November 30, 2022
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis
Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Drug
Study Drug: LY3454738
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
8-Week Atopic Dermatitis (AD) Treatment Study
8-Week Atopic Dermatitis (AD) Treatment Study
Enrollment Status: Completed
Publish Date: December 17, 2020
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Enrollment Status: Completed
Publish Date: November 20, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Pilot Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis
An Open-Label, Pilot Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks
A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks
Enrollment Status: Completed
Publish Date: September 19, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 13 Less Clinical Trials

16 Total Publications

Ruxolitinib Cream Versus Triamcinolone Cream in Adults With Mild to Moderate Atopic Dermatitis.
Ruxolitinib Cream Versus Triamcinolone Cream in Adults With Mild to Moderate Atopic Dermatitis.
Journal: Journal of drugs in dermatology : JDD
Published: October 02, 2025
Similar Doctors
Advanced in Intertrigo
Dr. Jeffrey M. Suchniak
Dermatology
Advanced in Intertrigo
Dr. Jeffrey M. Suchniak
Dermatology

Boice-Willis Clinic PA

45 B Guardian Ct, 
Rocky Mount, NC 
 (48.3 miles away)
252-937-0204
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Suchniak is a Dermatologist in Rocky Mount, North Carolina. Dr. Suchniak is rated as a Distinguished provider by MediFind in the treatment of Intertrigo. His top areas of expertise are Actinic Keratosis, Warts, Rosacea, and Seborrheic Keratosis. Dr. Suchniak is currently accepting new patients.

Advanced in Intertrigo
Dr. Dawn E. Kleinman
Dermatology
Advanced in Intertrigo
Dr. Dawn E. Kleinman
Dermatology

Sanford Dermatology, PLLC

100 S 10th St, 
Lillington, NC 
 (29.2 miles away)
919-775-7926
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Dawn Kleinman is a Dermatologist in Lillington, North Carolina. Dr. Kleinman is rated as a Distinguished provider by MediFind in the treatment of Intertrigo. Her top areas of expertise are Actinic Keratosis, Kaposiform Hemangioendothelioma, Fetal Cystic Hygroma, and Hemangioendothelioma. Dr. Kleinman is currently accepting new patients.

Advanced in Intertrigo
Dr. John D. Cheesborough
Dermatology
Advanced in Intertrigo
Dr. John D. Cheesborough
Dermatology

Sanford Dermatology, PLLC

827 S Horner Blvd, Suite B, 
Sanford, NC 
 (35.6 miles away)
919-775-7926
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Cheesborough is a Dermatologist in Sanford, North Carolina. Dr. Cheesborough is rated as a Distinguished provider by MediFind in the treatment of Intertrigo. His top areas of expertise are Actinic Keratosis, Nummular Eczema, Contact Dermatitis, and Acrogeria, Gottron Type. Dr. Cheesborough is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nasir's expertise for a condition
ConditionClose
      View All 59 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile